Cost-effectiveness of left Atrial appendage closure for stroke reduction in Atrial fibrillation: Analysis of pooled, 5-year, long-term data

Vivek Y. Reddy, Ronald L. Akehurst, Meghan B. Gavaghan, Stacey L. Amorosi, David Holmes

Research output: Contribution to journalArticle

Abstract

Background-Recent publications reached conflicting conclusions about the cost-effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation (AF). This analysis sought to assess the cost-effectiveness of LAAC relative to both warfarin and nonwarfarin oral anticoagulants (NOACs) using pooled, long-term data from the randomized PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin) trials. Methods and Results-A Markov model was constructed from a US payer perspective with a lifetime (20-year) horizon. LAAC clinical event rates and stroke outcomes were from pooled PROTECT AF and PREVAIL trial 5-year data. Warfarin and NOAC inputs were derived from published meta-analyses. The model was populated with a cohort of 10 000 patients, aged 70 years, at moderate stroke and bleeding risk. Sensitivity analyses were performed. LAAC was cost-effective relative to warfarin by year 7 ($48 674/quality-adjusted life-year) and dominant (more effective and less costly) by year 10. LAAC became cost-effective and dominant compared with NOACs by year 5. Over a lifetime, LAAC provided 0.60 more quality-adjusted life-years than warfarin and 0.29 more than NOACs. In sensitivity analyses, LAAC was cost-effective relative to warfarin and NOACs in 98% and 95% of simulations, respectively. Conclusions-Using pooled, 5-year PROTECT AF and PREVAIL trial data, LAAC proved to be not only cost-effective, but cost saving relative to warfarin and NOACs. LAAC with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.

Original languageEnglish (US)
Article numbere011577
JournalJournal of the American Heart Association
Volume8
Issue number13
DOIs
StatePublished - Jul 1 2019

Fingerprint

Atrial Appendage
Atrial Fibrillation
Cost-Benefit Analysis
Stroke
Warfarin
Anticoagulants
Costs and Cost Analysis
Quality-Adjusted Life Years
Risk Reduction Behavior
Equipment and Supplies
Meta-Analysis
Hemorrhage

Keywords

  • Anticoagulant
  • Atrial fibrillation
  • Cost-effectiveness
  • Left atrial appendage closure
  • Nonwarfarin oral anticoagulants
  • Watchman

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cost-effectiveness of left Atrial appendage closure for stroke reduction in Atrial fibrillation : Analysis of pooled, 5-year, long-term data. / Reddy, Vivek Y.; Akehurst, Ronald L.; Gavaghan, Meghan B.; Amorosi, Stacey L.; Holmes, David.

In: Journal of the American Heart Association, Vol. 8, No. 13, e011577, 01.07.2019.

Research output: Contribution to journalArticle

@article{b15b06da23f9441c807862c6ba933527,
title = "Cost-effectiveness of left Atrial appendage closure for stroke reduction in Atrial fibrillation: Analysis of pooled, 5-year, long-term data",
abstract = "Background-Recent publications reached conflicting conclusions about the cost-effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation (AF). This analysis sought to assess the cost-effectiveness of LAAC relative to both warfarin and nonwarfarin oral anticoagulants (NOACs) using pooled, long-term data from the randomized PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin) trials. Methods and Results-A Markov model was constructed from a US payer perspective with a lifetime (20-year) horizon. LAAC clinical event rates and stroke outcomes were from pooled PROTECT AF and PREVAIL trial 5-year data. Warfarin and NOAC inputs were derived from published meta-analyses. The model was populated with a cohort of 10 000 patients, aged 70 years, at moderate stroke and bleeding risk. Sensitivity analyses were performed. LAAC was cost-effective relative to warfarin by year 7 ($48 674/quality-adjusted life-year) and dominant (more effective and less costly) by year 10. LAAC became cost-effective and dominant compared with NOACs by year 5. Over a lifetime, LAAC provided 0.60 more quality-adjusted life-years than warfarin and 0.29 more than NOACs. In sensitivity analyses, LAAC was cost-effective relative to warfarin and NOACs in 98{\%} and 95{\%} of simulations, respectively. Conclusions-Using pooled, 5-year PROTECT AF and PREVAIL trial data, LAAC proved to be not only cost-effective, but cost saving relative to warfarin and NOACs. LAAC with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.",
keywords = "Anticoagulant, Atrial fibrillation, Cost-effectiveness, Left atrial appendage closure, Nonwarfarin oral anticoagulants, Watchman",
author = "Reddy, {Vivek Y.} and Akehurst, {Ronald L.} and Gavaghan, {Meghan B.} and Amorosi, {Stacey L.} and David Holmes",
year = "2019",
month = "7",
day = "1",
doi = "10.1161/JAHA.118.011577",
language = "English (US)",
volume = "8",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "13",

}

TY - JOUR

T1 - Cost-effectiveness of left Atrial appendage closure for stroke reduction in Atrial fibrillation

T2 - Analysis of pooled, 5-year, long-term data

AU - Reddy, Vivek Y.

AU - Akehurst, Ronald L.

AU - Gavaghan, Meghan B.

AU - Amorosi, Stacey L.

AU - Holmes, David

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background-Recent publications reached conflicting conclusions about the cost-effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation (AF). This analysis sought to assess the cost-effectiveness of LAAC relative to both warfarin and nonwarfarin oral anticoagulants (NOACs) using pooled, long-term data from the randomized PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin) trials. Methods and Results-A Markov model was constructed from a US payer perspective with a lifetime (20-year) horizon. LAAC clinical event rates and stroke outcomes were from pooled PROTECT AF and PREVAIL trial 5-year data. Warfarin and NOAC inputs were derived from published meta-analyses. The model was populated with a cohort of 10 000 patients, aged 70 years, at moderate stroke and bleeding risk. Sensitivity analyses were performed. LAAC was cost-effective relative to warfarin by year 7 ($48 674/quality-adjusted life-year) and dominant (more effective and less costly) by year 10. LAAC became cost-effective and dominant compared with NOACs by year 5. Over a lifetime, LAAC provided 0.60 more quality-adjusted life-years than warfarin and 0.29 more than NOACs. In sensitivity analyses, LAAC was cost-effective relative to warfarin and NOACs in 98% and 95% of simulations, respectively. Conclusions-Using pooled, 5-year PROTECT AF and PREVAIL trial data, LAAC proved to be not only cost-effective, but cost saving relative to warfarin and NOACs. LAAC with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.

AB - Background-Recent publications reached conflicting conclusions about the cost-effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation (AF). This analysis sought to assess the cost-effectiveness of LAAC relative to both warfarin and nonwarfarin oral anticoagulants (NOACs) using pooled, long-term data from the randomized PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin) trials. Methods and Results-A Markov model was constructed from a US payer perspective with a lifetime (20-year) horizon. LAAC clinical event rates and stroke outcomes were from pooled PROTECT AF and PREVAIL trial 5-year data. Warfarin and NOAC inputs were derived from published meta-analyses. The model was populated with a cohort of 10 000 patients, aged 70 years, at moderate stroke and bleeding risk. Sensitivity analyses were performed. LAAC was cost-effective relative to warfarin by year 7 ($48 674/quality-adjusted life-year) and dominant (more effective and less costly) by year 10. LAAC became cost-effective and dominant compared with NOACs by year 5. Over a lifetime, LAAC provided 0.60 more quality-adjusted life-years than warfarin and 0.29 more than NOACs. In sensitivity analyses, LAAC was cost-effective relative to warfarin and NOACs in 98% and 95% of simulations, respectively. Conclusions-Using pooled, 5-year PROTECT AF and PREVAIL trial data, LAAC proved to be not only cost-effective, but cost saving relative to warfarin and NOACs. LAAC with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.

KW - Anticoagulant

KW - Atrial fibrillation

KW - Cost-effectiveness

KW - Left atrial appendage closure

KW - Nonwarfarin oral anticoagulants

KW - Watchman

UR - http://www.scopus.com/inward/record.url?scp=85068580247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068580247&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.011577

DO - 10.1161/JAHA.118.011577

M3 - Article

C2 - 31230500

AN - SCOPUS:85068580247

VL - 8

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 13

M1 - e011577

ER -